Recent Updates
Recently added Catalysts
NVAX Positive Sentiment Score: 60/100

Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023

Key Takeaway: Novavax, Inc. announced a conference call scheduled for May 9, 2023, to discuss its first quarter financial results and operational highlights. The call will begin at 8:30 a.m. EDT, with details provided for domestic and international participants. The company emphasizes its role in advancing protein-based vaccines and addressing significant health challenges.

Market Sentiment Analysis

POSITIVE FACTORS

  • Novavax is hosting a conference call to discuss its financial results, indicating transparency.
  • The company continues to innovate in the vaccine space with its novel Matrix-M adjuvant.
  • Focus on serious infectious diseases showcases the company's commitment to public health.

Full Press Release Details

GAITHERSBURG, Md., May 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday, May 9, 2023. Details of the event and replay are as follows:
Conference call details:
Date: May 9, 2023
Time: 8:30 a.m. U.S. Eastern Daylight Time (EDT)
Dial-in number: (877) 883-0383 (Domestic) or (412) 902-6506 (International)
Passcode: 3370620
Webcast: ir.novavax.com/events
Participants will be prompted to request to join the Novavax, Inc. call.
To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details:
Date: Available starting at 11:30 a.m. EDT, May 9, 2023, until 11:59 p.m. U.S. EDT, May 16, 2023
Dial-in number: (877) 344-7529 (Domestic) or (412) 317-0088 (International)
Passcode: 1969560
Webcast: ir.novavax.com/events , until August 7, 2023
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
SOURCE Novavax, Inc.

21 %

more press release views with

Frequently Asked Questions

When will Novavax report its Q1 2023 financial results?

Novavax will report its Q1 2023 results on May 9, 2023, at 8:30 a.m. EDT.

What is the passcode for Novavax's conference call?

The passcode for the Novavax conference call is 3370620.

How long will the Novavax replay be available?

The Novavax replay will be available from May 9 to May 16, 2023.

What technology does Novavax use for its vaccines?

Novavax utilizes a recombinant protein approach and Matrix-M adjuvant.

What health issues is Novavax addressing with its vaccines?

Novavax focuses on COVID-19, influenza, and their combination for vaccination.

Last updated: May 2, 2023